Drugs / NBT-NM108
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04574024 | Mar 2022 → Jun 2024 | multiple sclerosis | Suhayl Dhib-Jalbut, MD | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05541003 | Jan → May 2023 | Prader-Willi syndrome, obesity disorder | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT05296681 | May 2022 → Dec 2026 expected | colorectal carcinoma, metastasis from malignant tumor of colon | Howard S. Hochster, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT04540406 | Nov 2021 → Mar 2022 | — | Notitia Biotechnologies Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBT-NM108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04574024 ↗ |
| Modality | Other / unclassified | “NBT-NM108 (a mixture of inulin, Fibersol-2, and brans of oat, wheat, corn and sorghum; Notitia Biotechnologies)” NCT05541003 ↗ |
| Route | Oral | “Taken in the form of drinks four times a day” NCT04540406 ↗ |